Biocryst Pharmaceuticals (BCRX) Research & Development (2010 - 2026)

Biocryst Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $60.3 million for Q1 2026.

• Quarterly Research & Development rose 61.84% year-over-year to $60.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $189.2 million (up 14.36% YoY) and the FY2025 annual result came in at $166.1 million, down 4.87% from the prior year.
• Research & Development was $60.3 million for Q1 2026 at Biocryst Pharmaceuticals, up from $40.9 million in the prior quarter.
• Across five years, Research & Development topped out at $73.2 million in Q4 2022 and bottomed at $37.3 million in Q1 2025.
• A 5-year average of $51.2 million and a median of $48.4 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development retreated 29.42% — and 2026, when it surged 61.84%.
• Biocryst Pharmaceuticals' Research & Development stood at $73.2 million in 2022, then declined by 4.31% to $70.1 million in 2023, then decreased by 29.42% to $49.4 million in 2024, then dropped by 17.34% to $40.9 million in 2025, then jumped by 47.6% to $60.3 million in 2026.
• Business Quant data shows BCRX's Research & Development at $60.3 million in Q1 2026, $40.9 million in Q4 2025, and $44.6 million in Q3 2025.